IMRX - NASDAQ

Immuneering Corporation

Immuneering Corporation

IMRXยทNASDAQ

$4.55

+3.4%
HealthcareBiotechnology

Immuneering Corporation, a biopharmaceutical company, focuses on the oncology and neuroscience product candidates. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 to treat solid tumors. The company also has five oncology programs in the discovery stage that are designed to target components of the MAPK or mTOR pathway; and two discovery stage neuroscience programs. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts. Immuneering Corporation was a former subsidiary of Teva Pharmaceutical Industries Limited.

StatementsValue Model

At a Glance

Live Snapshot
Market Cap$165.18M
EPS-1.2700
P/E Ratio-3.58
Earnings Date08/12/2026
Immuneering Corporation

Immuneering Corporation Fair Value Envelope

IMRX ยท NASDAQ

Our analysis suggests that IMRX has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $4.55, this represents a potential HIDDEN relative to our calculated worth for Immuneering Corporation.

HIDDEN
Intrinsic Value
Current Price: $4.55

Owner Earnings Valuation Tool

Warren Buffett's Owner Earnings DCF analysis for intrinsic value calculation

Historical Financial Data

Base year metrics used for projections

$
%
$
%
$
$

Projection Settings

Forecast period and terminal assumptions

%
%

DCF Valuation Summary

Calculation flow from present value to intrinsic value per share

Present Value-$739.7M
+ Cash & Equivalents$128.6M
Firm Value-$611.1M
- Debt$3.8M
Equity Value-$614.9M
/ Shares Outstanding36,302,338B
DCF Value-$17
OVERVALUED BY 472%

Owner Earnings Projections

Operating Cash Flow - Maintenance CapEx = Owner Earnings

Metric
Year 1
Year 2
Year 3
Year 4
Year 5
Year 6
Year 7
Year 8
Year 9
Year 10
Operating Cash Flow
-$53.2M
-$62.5M
-$73.4M
-$86.2M
-$101.2M
-$118.9M
-$139.6M
-$163.9M
-$192.5M
-$226.0M
Maintenance CapEx
-$33.4K
-$39.2K
-$46.1K
-$54.1K
-$63.5K
-$74.6K
-$87.6K
-$102.8K
-$120.7K
-$141.8K
Owner Earnings
-$53.3M
-$62.6M
-$73.5M
-$86.3M
-$101.3M
-$118.9M
-$139.7M
-$164.0M
-$192.6M
-$226.1M
Discount Factor
0.926
0.857
0.794
0.735
0.681
0.630
0.583
0.540
0.500
0.463
Present Value
-$49.3M
-$53.6M
-$58.3M
-$63.4M
-$68.9M
-$75.0M
-$81.5M
-$88.6M
-$96.3M
-$104.7M
Terminal Value represents 0.0% of Enterprise Value
Negative Owner Earnings
This company generates negative free cash flow. Consider adjusting maintenance CapEx percentage or check the financial data.

Related Guides

Blog Categories

Continue your IMRX research with focused valuation guides.

DCF Modeling

Improve assumptions for intrinsic value accuracy.

Forecasting

Calibrate growth paths and terminal value behavior.

WACC

Refine discount-rate logic for valuation quality.

Cost of Capital

Match risk profile to expected return assumptions.

Research Paths

Pick your next lens
1

Snapshot

Start with context, operating signals, and key market metrics.

2

Value Model

Stress test fair value across bear, base, and bull assumptions.

3

Statements

Validate revenue quality, margins, and balance sheet durability.

4

Earnings Call

Read management commentary and compare it with reported outcomes.

5

Dividends

Check payout sustainability and long-term distribution behavior.

6

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.